0001654954-22-016416.txt : 20221213 0001654954-22-016416.hdr.sgml : 20221213 20221213131829 ACCESSION NUMBER: 0001654954-22-016416 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221213 FILED AS OF DATE: 20221213 DATE AS OF CHANGE: 20221213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GSK PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15170 FILM NUMBER: 221459161 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS FORMER COMPANY: FORMER CONFORMED NAME: GLAXOSMITHKLINE PLC DATE OF NAME CHANGE: 20010105 6-K 1 a5456j.htm DIRECTOR/PDMR SHAREHOLDING a5456j
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of December 2022
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
GSK plc (the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
9 (partnership shares)
 
 
£14.6517
9 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
18 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford  
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
8 (partnership shares)

 
£14.6517
8 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume Price
16 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms S Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
9 (partnership shares)
 
 
£14.6517
9 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
18 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Jackson
b)
Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
9 (partnership shares)
 
 
£14.6517
9 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
18 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
President Corporate Development
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
8 (partnership shares)
 
 
£14.6517
8 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
16 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
8 (partnership shares)
 
 
£14.6517
8 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
16 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
8 (partnership shares)
 
 
£14.6517
8 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
16 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
9 (partnership shares)
 
 
£14.6517
9 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
18 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms V Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£14.6517
9 (partnership shares)
 
 
£14.6517
9 (matching shares)
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
18 Ordinary Shares
£14.6517
e)
Date of the transaction
2022-12-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: December 13, 2022
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc